With regard to the dosage of inhibitors, basic and clinical reports implied that near-complete (80 - 90%) inhibition of ERK signaling might be necessary to suppress tumor growth and achieve therapeutic efficacy62, 63. The gene discussed is MAPK1; the disease is neoplasm.